ADS-5102 in LID

Clinical Development Program

ADS-5102 is a chrono-synchronous amantadine therapy with potential applications across a number of chronic neurologic disorders. We are focusing initial development on the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD) and submitted a New Drug Application (NDA) for this indication to the U.S. Food and Drug Administration in October 2016.